Neonatal Alloimmune Thrombocytopenia: A Concise Review

Area of Science:

• Perinatology
• Neonatology
• Immunology

Background:

• Neonatal alloimmune thrombocytopenia (NAIT) is an uncommon platelet disorder.
• Caused by maternal alloimmunization to paternally inherited human-specific antigens (HPAs).
• Leads to low fetal/neonatal platelet counts, causing severe thrombocytopenia and intracranial hemorrhage in newborns.

Purpose of the Study:

• Discuss the pathophysiology, clinical manifestations, diagnosis, and treatment of NAIT.
• Explore the implications of NAIT on neonatal lifespan.
• Highlight the need for improved diagnostic and treatment strategies.

Main Methods:

• Conducted a literature review from 2014-2019.
• Utilized databases such as PubMed, CINAHL, and Google Scholar.
• Employed search terms including NAIT, neonatal alloimmune thrombocytopenia, newborn platelets, and intracranial bleeding.

Main Results:

• NAIT can impact first pregnancies and is often diagnosed late.
• Noninvasive HPA-1a typing screening tools show promise, potentially reducing NAIT risks by 75%.
• Current screening tools are not universally implemented, and prophylactic treatments are unavailable.

Conclusions:

• Universal screening and prophylactic treatment for NAIT are crucial for early in utero diagnosis and intervention.
• Increased healthcare provider awareness of NAIT is essential to differentiate it from other causes of thrombocytopenia.